Moderna, Inc. $MRNA Shares Purchased by Empowered Funds LLC

Empowered Funds LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 143.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,436 shares of the company’s stock after purchasing an additional 19,704 shares during the period. Empowered Funds LLC’s holdings in Moderna were worth $1,699,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in MRNA. Canton Hathaway LLC bought a new stake in Moderna during the 1st quarter valued at $31,000. Assetmark Inc. grew its stake in shares of Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares in the last quarter. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the second quarter valued at $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Moderna during the fourth quarter valued at $31,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In related news, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 119,406 shares of company stock worth $5,928,762. Corporate insiders own 10.80% of the company’s stock.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, for adults ages 50 and older. It is the first mRNA flu vaccine approved in the United States and Moderna’s fourth FDA-approved product, supporting the company’s effort to diversify beyond COVID-19. The company expects limited retail availability in the coming weeks. US FDA approves first mRNA flu shot from Moderna
• Positive Sentiment: On its second-quarter earnings call, Moderna maintained its 2026 growth target while lowering cost guidance. The combination of preserved revenue expectations and lower spending could improve cash runway and reduce concerns about the company’s post-pandemic revenue decline. Management also highlighted upcoming milestones for flu, oncology and rare-disease programs. Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
• Positive Sentiment: Moderna began a Phase 1 Canadian trial of an investigational mRNA vaccine for Bundibugyo ebolavirus, a strain without an approved vaccine. Although early-stage, the program reinforces the breadth of Moderna’s infectious-disease platform and its partnerships with CEPI and Canadian public-health authorities. Moderna Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
• Neutral Sentiment: The flu approval is a meaningful commercial opportunity, but Moderna still needs CDC recommendations, distribution and physician adoption to translate the regulatory win into material revenue. The initial authorization is limited to adults 50 and older, with established flu vaccines already competing for the upcoming season. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
• Negative Sentiment: Investors continue to face substantial execution risk: COVID-related revenue has fallen sharply from pandemic highs, Moderna remains loss-making, and future valuation depends heavily on successful Phase 3 oncology results and broader pipeline commercialization. Some brokerages maintain a “Reduce” view, limiting the immediate impact of the positive headlines.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. The Goldman Sachs Group raised their target price on shares of Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a research note on Tuesday, July 21st. Bank of America boosted their price target on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Wolfe Research reaffirmed an “underperform” rating and issued a $25.00 price target on shares of Moderna in a research note on Monday, July 20th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $42.13.

Moderna Trading Up 9.9%

Shares of MRNA stock opened at $59.17 on Friday. The stock has a 50-day simple moving average of $60.28 and a 200 day simple moving average of $53.12. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The stock has a market capitalization of $23.62 billion, a P/E ratio of -7.41 and a beta of 0.91. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the company earned ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts expect that Moderna, Inc. will post -6.2 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.